Silo Pharma, Inc.

Silo Pharma, Inc. is a U.S.-based developmental-stage biopharmaceutical company focused on licensing, developing, and advancing drug candidates for central nervous system and stress-related disorders. Its pipeline includes intranasal, implantable, and peptide-based programs, and the company also holds digital assets as part of a treasury strategy.

38,6 %

−5 863,5 %

11.36

11.36

— Silo Pharma, Inc.
%
Lead therapeutic programs70% Development-stage drug candidates targeting PTSD, anxiety, fibromyalgia, and CNS disorders.
Drug delivery technology15% Intranasal and other delivery mechanisms used to improve targeting and onset of action.
Licensed intellectual property10% Exclusive and option-based rights to external inventions and patents supporting the pipeline.
Digital asset treasury5% Cryptocurrency holdings and related treasury activities outside the core therapeutics business.

Silo Pharma does not sell commercial medicines at scale; its economic counterparties are primarily licensors, research...

  • IP licensors and research institutionsprimary

    Provide patents, compounds, or delivery technologies that Silo licenses to build its pipeline.

  • Clinical development partnersprimary

    Support preclinical, toxicology, and regulatory-enabling studies for candidate advancement.

  • Future specialty-care patientsemerging

    Patients with PTSD, stress-induced anxiety, fibromyalgia, Alzheimer’s disease, or neuroinflammatory conditions who would use approved products.

  • Healthcare providersemerging

    Psychiatrists, neurologists, pain specialists, and other clinicians who would prescribe or administer therapies.

Silo Pharma is headquartered in the United States and conducts its business through U.S...

  • •Headquartered in the United States
  • •Regulatory interactions are centered on the U.S. FDA
  • •Licensing and research rights may be worldwide for some programs
  • •Development work is driven by U.S.-based corporate operations
  • •No country-level revenue disclosure was provided in the excerpts

Silo Pharma’s strategy is to license or acquire external intellectual property, fund development, and advance a small...

01
Advance SPC-15 through regulatory developmentshort-term

SPC-15 is the lead program and the clearest path to a clinical-stage asset.

02
Build a broader CNS and pain pipelinemedium-term

Multiple programs reduce dependence on a single asset and expand optionality.

03
License external IP and technology rightsmedium-term

The company relies on external inventions to source differentiated candidates.

04
Develop digital asset treasury capabilitiesshort-term

The treasury strategy creates a separate investment framework and capital use case.

Silo Pharma faces the typical risks of a development-stage biotech company: clinical, regulatory, and intellectual...

high

Pipeline development and regulatory risk

Drug candidates must clear preclinical, IND, and clinical hurdles before commercialization.

Scope
SPC-15, SP-26, SPC-14, SPU-16
Materiality
high
high

Intellectual property and licensing dependence

The business depends on rights from third parties and may face renewal, scope, or royalty constraints.

Scope
Medspray license, UMB option, university-originated assets
Materiality
high
high

Cryptocurrency market and treasury execution risk

Digital assets can be volatile and operational mistakes in custody or trading can create losses.

Scope
Bitcoin, Ethereum, Solana, digital asset holdings
Materiality
high
medium

Nasdaq listing and financing risk

Maintaining exchange listing supports liquidity and access to capital for a pre-revenue biotech.

Scope
Common stock market access
Materiality
medium
medium

Competition in CNS and psychedelic medicine

Other developers are pursuing similar indications, delivery methods, and assets.

Scope
PTSD, anxiety, fibromyalgia, Alzheimer’s, neuroinflammatory disease
Materiality
medium
Research and development expense recognition
Can create volatility in quarterly operating results
Stock-based compensation
Affects operating expenses and diluted share count
License revenue recognition
Produces small, deferred revenue recognition rather than upfront sales
Digital asset accounting
Can materially affect other income and balance sheet values

Xilio Therapeutics, Inc.

XLO · Pharmaceutical Preparations

Lundbergföretagen

LUND-B.ST · Financials

MEKO

MEKO.ST · Consumer Discretionary

BE Group

BEGR.ST · Basic Materials

Nyfosa

NYF.ST · Real Estate

XANO Industri

XANO-B.ST · Industrials

: 29.4.2026